Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.30
-0.1000-0.69%
Post-market: 14.25-0.0500-0.35%17:04 EDT
Volume:3.25M
Turnover:46.56M
Market Cap:1.41B
PE:-2.45
High:14.70
Open:14.43
Low:14.13
Close:14.40
52wk High:39.89
52wk Low:13.81
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.31
T/O Rate:4.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.83
PE(LYR):-2.45

Loading ...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Medpace Holdings (MEDP) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 24

Wedbush Lifts Price Target on Ultragenyx Pharmaceutical to $27 From $25, Keeps Neutral Rating

MT Newswires Live
·
Apr 21

Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 17

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

TIPRANKS
·
Apr 16

BROAD ARROW AUCTIONS TO OFFER EXTREMELY RARE GORDON MURRAY AUTOMOTIVE T.50 VIA LIVE AUCTION DURING THE CALIFORNIA MILLE

GlobeNewswire
·
Apr 11

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 09

Ultragenyx says FDA accepts UX111 gene therapy BLA resubmission, sets Sept. 19 PDUFA date

Reuters
·
Apr 02

Ultragenyx Pharmaceutical Inc - FDA Sets Pdufa Action Date for Ux111 on September 19, 2026

THOMSON REUTERS
·
Apr 02

Ultragenyx Announces U.S. FDA Acceptance of Bla Resubmission for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
Apr 02

Ultragenyx Pharmaceutical Inc - Ux111 to Be Manufactured in U.S. at Andelyn Biosciences and Ultragenyx Facility IF Approved

THOMSON REUTERS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

Ultragenyx announces FDA clearance of UX016 investigational new drug application

TIPRANKS
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BUZZ-Ultragenyx rises after FDA clears human trial for rare muscle disease drug

Reuters
·
Mar 30

Ultragenyx wins FDA IND clearance for UX016 in GNE myopathy

Reuters
·
Mar 30

Ultragenyx Pharmaceutical Inc - Phase 1/2 Study of Ux016 Expected to Begin in H2 2026

THOMSON REUTERS
·
Mar 30

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump?

Simply Wall St.
·
Mar 29

Ultragenyx announces annual stockholders meeting; FY2025 revenue grows 20%

Reuters
·
Mar 28

BROAD ARROW PRESENTS RARE OPPORTUNITY TO ACQUIRE FERRARI MONZA SP2 AT CONCORSO D’ELEGANZA VILLA D’ESTE AUCTION

GlobeNewswire
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Mar 25